INOVIO (NASDAQ:INO) Announces That 94% of the 36 Participants in the Phase 1 Clinical Trial Reacted Positively to Its Vaccine Candidate
https://wccftech.com/inovio-nasdaqino-announces-that-94-of-the-36-participants-in-the-phase-1-clinical-trial-reacted-positively-to-its-vaccine-candidate/
INOVIO Pharmaceuticals (NASDAQ:INO), one of a handful of biotechnology companies trying to formulate an effective vaccine against the ongoing coronavirus (COVID-19) pandemic, announced encouraging phase 1 clinical trial results today.
According to a statement released by INOVIO just moments ago, its vaccine candidate – formally known as INO-4800 – depicted encouraging results during the ongoing phase 1 clinical trial. Specifically, the statement noted:
INOVIO (NASDAQ:INO) Announces That 94% of the 36 Participants in the Phase 1 Clinical Trial Reacted Positively to Its Vaccine Candidate
Jun 30, 2020, 1:17pm UTC
https://wccftech.com/inovio-nasdaqino-announces-that-94-of-the-36-participants-in-the-phase-1-clinical-trial-reacted-positively-to-its-vaccine-candidate/
> INOVIO Pharmaceuticals (NASDAQ:INO), one of a handful of biotechnology companies trying to formulate an effective vaccine against the ongoing coronavirus (COVID-19) pandemic, announced encouraging phase 1 clinical trial results today.
> According to a statement released by INOVIO just moments ago, its vaccine candidate – formally known as INO-4800 – depicted encouraging results during the ongoing phase 1 clinical trial. Specifically, the statement noted: